


Artemisone

Cat. No.:	HY-19502		
CAS No.:	255730-18-8		
Molecular Formula:	C ₁₉ H ₃₁ NO ₆ S		
Molecular Weight:	401.52		
Target:	Parasite; CMV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 130 mg/mL (323.77 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.4905 mL	12.4527 mL	24.9054 mL
		5 mM	0.4981 mL	2.4905 mL	4.9811 mL
10 mM		0.2491 mL	1.2453 mL	2.4905 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (5.40 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.17 mg/mL (5.40 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.17 mg/mL (5.40 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Artemisone (Artemifone) is a potent and semi-synthetic antimalarial, inhibits <i>P. falciparum</i> strains, with a mean IC ₅₀ of 0.83 nM ^[1] . Artemisone is also a potent inhibitor of human CMV ^[2] .
IC₅₀ & Target	IC ₅₀ : 0.83 nM (<i>P. falciparum</i>) ^[1]
In Vitro	Artemisone inhibits 3D7 and K1 <i>P. falciparum</i> , with IC ₅₀ s of 0.88±0.59 and 1.23±0.64 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Artemisone is effective at inhibiting the parasitaemia in the *P. berghei* NY susceptible strain, with an ED₅₀ of 9.62 mg/kg via subcutaneous route and 11.67 mg/kg via oral administration^[1].

Artemisone (3, 1, 0.3 and 0.1 mg/kg, s.c.) in combination with other antimalarials has enhanced effect against the chloroquine-resistant line *P. yoelii* NS^[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Vivas L, et al. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. *J Antimicrob Chemother.* 2007 Apr;59(4):658-65.

[2]. Ruiyuan Cao, et al. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro. *ACS Infect. Dis.* 2020 Jul.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA